Combination strategies with checkpoint immunotherapy and inducers of immunogenic cell death (ICD) in immune competent syngeneic models

被引：0
|
作者：
McKenzie, A. [1 ]
Papadopoulou, N. [1 ]
Yin, Y. [1 ]
Jiang, S. [1 ]
Wrigley, J. [2 ]
King, J. [3 ]
Garland, R. [4 ]
Williams, N. [5 ]
Kumari, R. [6 ]
机构：
[1] Crown Biosci UK Ltd, Sci Operat, Loughborough, Leics, England
[2] Crown Biosci UK Ltd, Vitro Operat, Loughborough, Leics, England
[3] Crown Biosci UK Ltd, Vivo Operat, Loughborough, Leics, England
[4] KWS Biotest, Analyt Serv, Bristol, Avon, England
[5] KWS Biotest, Bristol, Avon, England
[6] Crown Biosci UK Ltd, CBUK, Loughborough, Leics, England
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 69卷
关键词：
D O I：
10.1016/S0959-8049(16)32931-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
338
引用
收藏
页码：S111 / S112
页数：2
相关论文
共 50 条
  • [31] Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction
    Mardi, Amirhossein
    Shirokova, Anastasia, V
    Mohammed, Rebar N.
    Keshavarz, Ali
    Zekiy, Angelina O.
    Thangavelu, Lakshmi
    Mohamad, Talar Ahmad Merza
    Marofi, Faroogh
    Shomali, Navid
    Zamani, Amir
    Akbari, Morteza
    CANCER CELL INTERNATIONAL, 2022, 22 (01)
  • [32] Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
    Sparks, R.
    Rolland, S.
    Klinz, S.
    Meyer-Losic, F.
    Nakhle, J.
    Delille, R.
    de Boisferonc, M. Hillairet
    ANNALS OF ONCOLOGY, 2019, 30
  • [33] Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumor mouse models
    Rolland, S.
    Klinz, S. G.
    Meyer-Losic, F.
    Nahkle, J.
    Delille, R.
    de Boisferon, M. Hillairet
    ANNALS OF ONCOLOGY, 2018, 29
  • [34] ARMED MYXOMA VIRUS DEMONSTRATES EFFICACY IN SYNGENEIC TUMOR MODELS ALONE AND IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS
    Franco, Lina
    Torres-Dominguez, Lino
    Mamola, Joseph
    de Matos, Ana
    Abrantes, Mario
    Walker, Benjamin
    Tacner, Zachary
    Kien, Cassandra
    Elliott, Natalie
    McFadden, Grant
    Sharp, Leslie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A356 - A356
  • [35] Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy
    Xie, Lisi
    Wang, Guohao
    Sang, Wei
    Li, Jie
    Zhang, Zhan
    Li, Wenxi
    Yan, Jie
    Zhao, Qi
    Dai, Yunlu
    BIOMATERIALS, 2021, 269
  • [36] Immunogenic cell death (ICD) genes predict immunotherapy response and therapeutic targets in acute myeloid leukemia (AML)
    Wen, Shuang
    Lv, Xuefeng
    Ma, Xiaohan
    Deng, Shu
    Xie, Jinming
    Yuan, Enwu
    FRONTIERS IN GENETICS, 2024, 15
  • [37] Evaluation of tumour infiltrating immune cells into the orthotopic and metastatic tumour microenvironment using bioluminescent syngeneic cell line models in immune competent mice following treatment with checkpoint inhibitors
    Andrew, M.
    Nektaria, P.
    Simon, J.
    Jane, W.
    Jason, K.
    Vicky, L.
    Kelly, J.
    Russell, G.
    Neil, W.
    Kumari, R.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S111 - S111
  • [38] Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy
    Zhou, Lei
    Zhang, Pengcheng
    Wang, Hao
    Wang, Dangge
    Li, Yaping
    ACCOUNTS OF CHEMICAL RESEARCH, 2020, 53 (09) : 1761 - 1772
  • [39] Quantitative cell-based bioassays to advance individual or combination immune checkpoint immunotherapy
    Grailer, Jamison
    Gilden, Julia
    Stecha, Pete
    Garvin, Denise
    Hartnett, Jim
    Fan, Frank
    Cong, Mei
    Cheng, Zhi-Jie Jey
    CANCER RESEARCH, 2018, 78 (13)
  • [40] Quantitative cell-based bioassays to advance individual or combination immune checkpoint immunotherapy
    Grailer, Jamison
    Stecha, Pete
    Garvin, Denise
    Hartnett, Jim
    Fan, Frank
    Cong, Mei
    Cheng, Zhi-Jie Jey
    CANCER RESEARCH, 2017, 77
12345